Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Sep;62(3):398–404. doi: 10.1038/bjc.1990.306

Analysis of the c-Ha-ras-1 gene for deletion, mutation, amplification and expression in lymph node metastases of human head and neck carcinomas.

Z M Sheng 1, M Barrois 1, J Klijanienko 1, C Micheau 1, J M Richard 1, G Riou 1
PMCID: PMC1971465  PMID: 1698442

Abstract

The c-Ha-ras gene was analysed by Southern blot hybridisation in 67 specimens of lymph node metastases and in 25 specimens of primary tumours obtained from 85 untreated patients with head and neck squamous cell carcinoma. The loss of one c-Ha-ras allele was observed in 10/46 (22%) tumours from heterozygous patients for this locus. Different genes, located as the c-Ha-ras gene on the short arm of chromosome 11, were also found to be deleted suggesting that the deletion of other genes could play a role in aggressiveness of head and neck carcinomas. Using polymerase chain reaction, mutation at codon 12 was detected in only 2/54 (3.8%) tumours but no mutation involving codon 61 was found. Neither gene amplification nor gene rearrangement could be observed. Total RNA was prepared from 79 of these tumour specimens and analysed by Northern and slot blot hybridisation. A 1.2 kb c-Ha-ras transcript band was detected in all the RNA preparations. Relatively high c-Ha-ras transcript levels were found in 18% of lymph node metastases and in 21% of primary tumours, indicating no significant differences between these cancers. Moreover, the c-Ha-ras mRNA levels were not significantly greater in the primary tumours than in the normal mucosae in 10/12 cases for which both tissues were analysed. These data indicate that c-Ha-ras gene does not seem to be strongly involved in head and neck carcinomas at that advanced stage of the disease, as this was previously reported for earlier clinical stages.

Full text

PDF
398

Images in this article

399Figure 1
on p.399
400Figure 3
on p.400
401Figure 4
on p.401
401Figure 6
on p.401
401Figure 7
on p.401
401Figure 8
on p.401

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ali I. U., Lidereau R., Theillet C., Callahan R. Reduction to homozygosity of genes on chromosome 11 in human breast neoplasia. Science. 1987 Oct 9;238(4824):185–188. doi: 10.1126/science.3659909. [DOI] [PubMed] [Google Scholar]
  2. Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988 May 20;53(4):549–554. doi: 10.1016/0092-8674(88)90571-5. [DOI] [PubMed] [Google Scholar]
  3. Antonarakis S. E., Boehm C. D., Giardina P. J., Kazazian H. H., Jr Nonrandom association of polymorphic restriction sites in the beta-globin gene cluster. Proc Natl Acad Sci U S A. 1982 Jan;79(1):137–141. doi: 10.1073/pnas.79.1.137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barker D., Holm T., White R. A locus on chromosome 11p with multiple restriction site polymorphisms. Am J Hum Genet. 1984 Nov;36(6):1159–1171. [PMC free article] [PubMed] [Google Scholar]
  5. Bishop J. M. The molecular genetics of cancer. Science. 1987 Jan 16;235(4786):305–311. doi: 10.1126/science.3541204. [DOI] [PubMed] [Google Scholar]
  6. Blot W. J., McLaughlin J. K., Winn D. M., Austin D. F., Greenberg R. S., Preston-Martin S., Bernstein L., Schoenberg J. B., Stemhagen A., Fraumeni J. F., Jr Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1988 Jun 1;48(11):3282–3287. [PubMed] [Google Scholar]
  7. Bos J. L., Fearon E. R., Hamilton S. R., Verlaan-de Vries M., van Boom J. H., van der Eb A. J., Vogelstein B. Prevalence of ras gene mutations in human colorectal cancers. 1987 May 28-Jun 3Nature. 327(6120):293–297. doi: 10.1038/327293a0. [DOI] [PubMed] [Google Scholar]
  8. Bos J. L. ras oncogenes in human cancer: a review. Cancer Res. 1989 Sep 1;49(17):4682–4689. [PubMed] [Google Scholar]
  9. Bourhis J., Bénard J., Hartmann O., Boccon-Gibod L., Lemerle J., Riou G. Correlation of MDR1 gene expression with chemotherapy in neuroblastoma. J Natl Cancer Inst. 1989 Sep 20;81(18):1401–1405. doi: 10.1093/jnci/81.18.1401. [DOI] [PubMed] [Google Scholar]
  10. Chesa P. G., Rettig W. J., Melamed M. R., Old L. J., Niman H. L. Expression of p21ras in normal and malignant human tissues: lack of association with proliferation and malignancy. Proc Natl Acad Sci U S A. 1987 May;84(10):3234–3238. doi: 10.1073/pnas.84.10.3234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Clair T., Miller W. R., Cho-Chung Y. S. Prognostic significance of the expression of a ras protein with a molecular weight of 21,000 by human breast cancer. Cancer Res. 1987 Oct 15;47(20):5290–5293. [PubMed] [Google Scholar]
  12. Craig R. K., Hall L., Edbrooke M. R., Allison J., MacIntyre I. Partial nucleotide sequence of human calcitonin precursor mRNA identifies flanking cryptic peptides. Nature. 1982 Jan 28;295(5847):345–347. doi: 10.1038/295345a0. [DOI] [PubMed] [Google Scholar]
  13. Field J. K., Lamothe A., Spandidos D. A. Clinical relevance of oncogene expression in head and neck tumours. Anticancer Res. 1986 Jul-Aug;6(4):595–600. [PubMed] [Google Scholar]
  14. Forrester K., Almoguera C., Han K., Grizzle W. E., Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. 1987 May 28-Jun 3Nature. 327(6120):298–303. doi: 10.1038/327298a0. [DOI] [PubMed] [Google Scholar]
  15. Friend S. H., Dryja T. P., Weinberg R. A. Oncogenes and tumor-suppressing genes. N Engl J Med. 1988 Mar 10;318(10):618–622. doi: 10.1056/NEJM198803103181007. [DOI] [PubMed] [Google Scholar]
  16. Furth M. E., Aldrich T. H., Cordon-Cardo C. Expression of ras proto-oncogene proteins in normal human tissues. Oncogene. 1987 Mar;1(1):47–58. [PubMed] [Google Scholar]
  17. Gallick G. E., Kurzrock R., Kloetzer W. S., Arlinghaus R. B., Gutterman J. U. Expression of p21ras in fresh primary and metastatic human colorectal tumors. Proc Natl Acad Sci U S A. 1985 Mar;82(6):1795–1799. doi: 10.1073/pnas.82.6.1795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Guérin M., Gabillot M., Mathieu M. C., Travagli J. P., Spielmann M., Andrieu N., Riou G. Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer. 1989 Feb 15;43(2):201–208. doi: 10.1002/ijc.2910430205. [DOI] [PubMed] [Google Scholar]
  19. Kerr I. B., Lee F. D., Quintanilla M., Balmain A. Immunocytochemical demonstration of p21 ras family oncogene product in normal mucosa and in premalignant and malignant tumours of the colorectum. Br J Cancer. 1985 Nov;52(5):695–700. doi: 10.1038/bjc.1985.245. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Korneluk R. G., Quan F., Lewis W. H., Guise K. S., Willard H. F., Holmes M. T., Gravel R. A. Isolation of human fibroblast catalase cDNA clones. Sequence of clones derived from spliced and unspliced mRNA. J Biol Chem. 1984 Nov 25;259(22):13819–13823. [PubMed] [Google Scholar]
  21. Krontiris T. G., DiMartino N. A., Colb M., Parkinson D. R. Unique allelic restriction fragments of the human Ha-ras locus in leukocyte and tumour DNAs of cancer patients. 1985 Jan 31-Feb 6Nature. 313(6001):369–374. doi: 10.1038/313369a0. [DOI] [PubMed] [Google Scholar]
  22. Lemoine N. R., Mayall E. S., Wyllie F. S., Farr C. J., Hughes D., Padua R. A., Thurston V., Williams E. D., Wynford-Thomas D. Activated ras oncogenes in human thyroid cancers. Cancer Res. 1988 Aug 15;48(16):4459–4463. [PubMed] [Google Scholar]
  23. Merkel D. E., McGuire W. L. Oncogenes and cancer prognosis. Important Adv Oncol. 1988:103–117. [PubMed] [Google Scholar]
  24. Ocadiz R., Sauceda R., Cruz M., Graef A. M., Gariglio P. High correlation between molecular alterations of the c-myc oncogene and carcinoma of the uterine cervix. Cancer Res. 1987 Aug 1;47(15):4173–4177. [PubMed] [Google Scholar]
  25. Parkin D. M., Stjernswärd J., Muir C. S. Estimates of the worldwide frequency of twelve major cancers. Bull World Health Organ. 1984;62(2):163–182. [PMC free article] [PubMed] [Google Scholar]
  26. Riou G. F. Proto-oncogenes and prognosis in early carcinoma of the uterine cervix. Cancer Surv. 1988;7(3):441–456. [PubMed] [Google Scholar]
  27. Riou G., Barrois M., Sheng Z. M., Duvillard P., Lhomme C. Somatic deletions and mutations of c-Ha-ras gene in human cervical cancers. Oncogene. 1988 Sep;3(3):329–333. [PubMed] [Google Scholar]
  28. Riou G., Barrois M., Tordjman I., Dutronquay V., Orth G. Présence de génomes de papillomavirus et amplification des oncogènes c-myc et c-Ha-ras dans des cancers envahissants du col de l'utérus. C R Acad Sci III. 1984;299(14):575–580. [PubMed] [Google Scholar]
  29. Saiki R. K., Scharf S., Faloona F., Mullis K. B., Horn G. T., Erlich H. A., Arnheim N. Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science. 1985 Dec 20;230(4732):1350–1354. doi: 10.1126/science.2999980. [DOI] [PubMed] [Google Scholar]
  30. Seeger R. C., Brodeur G. M., Sather H., Dalton A., Siegel S. E., Wong K. Y., Hammond D. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985 Oct 31;313(18):1111–1116. doi: 10.1056/NEJM198510313131802. [DOI] [PubMed] [Google Scholar]
  31. Sheng Z. M., Guerin M., Gabillot M., Spielmann M., Riou G. c-Ha-ras-1 polymorphism in human breast carcinomas: evidence for a normal distribution of alleles. Oncogene Res. 1988 Feb;2(3):245–250. [PubMed] [Google Scholar]
  32. Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., McGuire W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987 Jan 9;235(4785):177–182. doi: 10.1126/science.3798106. [DOI] [PubMed] [Google Scholar]
  33. Spandidos D. A., Kerr I. B. Elevated expression of the human ras oncogene family in premalignant and malignant tumours of the colorectum. Br J Cancer. 1984 Jun;49(6):681–688. doi: 10.1038/bjc.1984.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Spandidos D. A., Lamothe A., Field J. K. Multiple transcriptional activation of cellular oncogenes in human head and neck solid tumours. Anticancer Res. 1985 Mar-Apr;5(2):221–224. [PubMed] [Google Scholar]
  35. Suárez H. G., Du Villard J. A., Caillou B., Schlumberger M., Tubiana M., Parmentier C., Monier R. Detection of activated ras oncogenes in human thyroid carcinomas. Oncogene. 1988 Apr;2(4):403–406. [PubMed] [Google Scholar]
  36. Tanaka T., Slamon D. J., Shimoda H., Waki C., Kawaguchi Y., Tanaka Y., Ida N. Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with a patient's prognosis. Cancer Res. 1988 Feb 15;48(4):1030–1034. [PubMed] [Google Scholar]
  37. Tuyns A. J., Estève J., Raymond L., Berrino F., Benhamou E., Blanchet F., Boffetta P., Crosignani P., del Moral A., Lehmann W. Cancer of the larynx/hypopharynx, tobacco and alcohol: IARC international case-control study in Turin and Varese (Italy), Zaragoza and Navarra (Spain), Geneva (Switzerland) and Calvados (France). Int J Cancer. 1988 Apr 15;41(4):483–491. doi: 10.1002/ijc.2910410403. [DOI] [PubMed] [Google Scholar]
  38. Vasicek T. J., McDevitt B. E., Freeman M. W., Fennick B. J., Hendy G. N., Potts J. T., Jr, Rich A., Kronenberg H. M. Nucleotide sequence of the human parathyroid hormone gene. Proc Natl Acad Sci U S A. 1983 Apr;80(8):2127–2131. doi: 10.1073/pnas.80.8.2127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Verlaan-de Vries M., Bogaard M. E., van den Elst H., van Boom J. H., van der Eb A. J., Bos J. L. A dot-blot screening procedure for mutated ras oncogenes using synthetic oligodeoxynucleotides. Gene. 1986;50(1-3):313–320. doi: 10.1016/0378-1119(86)90335-5. [DOI] [PubMed] [Google Scholar]
  40. Viola M. V., Fromowitz F., Oravez S., Deb S., Finkel G., Lundy J., Hand P., Thor A., Schlom J. Expression of ras oncogene p21 in prostate cancer. N Engl J Med. 1986 Jan 16;314(3):133–137. doi: 10.1056/NEJM198601163140301. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES